Log in

Zacks Investment Research Upgrades Sapiens International (NASDAQ:SPNS) to Buy

Last updated on Wednesday, July 1, 2020 | 2020 MarketBeat

Sapiens International (NASDAQ:SPNS) was upgraded by Zacks Investment Research from a "hold" rating to a "buy" rating in a report released on Wednesday, Zacks.com reports. The firm currently has a $30.00 price objective on the technology company's stock. Zacks Investment Research's target price points to a potential upside of 8.46% from the stock's current price.

According to Zacks, "SAPIENS INTL NV is a leading global provider of proven IT solutions that modernize business processes and enable insurance organizations and other leading companies to adapt quickly to change. Serving as consultants and advisors, Sapiens works with companies to analyze their current systems and develop a blueprint for aligning technology with business goals. The company focuses on delivering innovative solutions that allow companies to build on existing IT assets. "

Several other equities research analysts have also recently weighed in on SPNS. ValuEngine upgraded Sapiens International from a "sell" rating to a "hold" rating in a research report on Tuesday, March 3rd. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of Sapiens International in a research report on Thursday, May 14th. Finally, BidaskClub cut shares of Sapiens International from a "buy" rating to a "hold" rating in a research report on Tuesday. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of "Hold" and a consensus price target of $22.94.

Shares of SPNS traded down $0.32 during midday trading on Wednesday, hitting $27.66. 11,114 shares of the company traded hands, compared to its average volume of 459,285. The stock has a 50-day moving average of $26.07 and a 200-day moving average of $23.52. Sapiens International has a one year low of $13.55 and a one year high of $29.73. The firm has a market cap of $1.33 billion, a P/E ratio of 50.29, a PEG ratio of 6.51 and a beta of 1.16. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.14 and a quick ratio of 1.14.

Sapiens International (NASDAQ:SPNS) last announced its quarterly earnings results on Thursday, May 14th. The technology company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.19 by $0.01. Sapiens International had a return on equity of 17.81% and a net margin of 8.22%. The firm had revenue of $90.53 million for the quarter, compared to analysts' expectations of $87.07 million. Sell-side analysts forecast that Sapiens International will post 0.81 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of SPNS. Norges Bank purchased a new stake in shares of Sapiens International during the fourth quarter valued at approximately $15,498,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Sapiens International by 33.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 709,805 shares of the technology company's stock valued at $13,500,000 after purchasing an additional 176,964 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Sapiens International during the first quarter valued at approximately $2,180,000. Renaissance Technologies LLC boosted its stake in shares of Sapiens International by 15.1% during the fourth quarter. Renaissance Technologies LLC now owns 736,900 shares of the technology company's stock valued at $16,949,000 after purchasing an additional 96,500 shares during the period. Finally, Royal Bank of Canada boosted its stake in shares of Sapiens International by 40.2% during the first quarter. Royal Bank of Canada now owns 327,534 shares of the technology company's stock valued at $6,230,000 after purchasing an additional 93,894 shares during the period. Institutional investors and hedge funds own 15.83% of the company's stock.

Sapiens International Company Profile

Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, Europe, the Asia Pacific, and South Africa. The company offers software platform and solutions for personal, commercial, and specialty lines, as well as reinsurance and workers' compensation, including Sapiens CoreSuite and Sapiens IDITSuite; and life, pension, and annuities, such as Sapiens CoreSuite, Sapiens UnderwritingPro, Sapiens ApplicationPro, Sapiens IllustrationPro, and Sapiens ConsolidationMaster.

Featured Story: What is Blockchain?

Get a free copy of the Zacks research report on Sapiens International (SPNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

15 Healthcare Stocks that Analysts Love

There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems and other healthcare stocks, it can be hard to identify which healthcare companies are going to outperform the market.

Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same healthcare stock.

This slide show lists the 15 healthcare companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

View the "15 Healthcare Stocks that Analysts Love".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.